Key facts
- CorrectSequence Therapeutics reports positive 15-month follow-up data for CS-206.
- The therapy shows durable efficacy in treating sickle cell disease.
- No vaso-occlusive crises were observed in treated patients.
- The therapy demonstrated a favorable safety profile.
CorrectSequence Therapeutics Co, Ltd. (Correctseq), a clinical-stage biotechnology company, has announced positive 15-month follow-up data for its CS-206 therapy. This high-precision base editing treatment for sickle cell disease has demonstrated durable efficacy. The data indicates that patients treated with CS-206 experienced no vaso-occlusive crises and maintained a favorable safety profile throughout the follow-up period. Correctseq is pioneering transformer Base Editing technology.